Highbridge Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Highbridge Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-250,000	Closed	-$4.69M	–	1253
2018 Q1	$4.69M	Buy	+250,000	New	+$4.08M	0.08%	302
2017 Q1	–	Sell	-22,737	Closed	-$554K	–	1655
2016 Q4	$554K	Buy	22,737 +14,707	+183%	+$420K	0.01%	734
2016 Q3	$305K	Buy	+8,030	New	+$253K	﹤0.01%	998

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Highbridge Capital Management's RCKT Position: Q2 2018 in Review

Highbridge Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2018, closing a stake of 250,000 shares — an estimated $4.69M sold.

Highbridge Capital Management first reported a position in RCKT in Q3 2016 and held it in 3 quarters. The position peaked at $4.69M in Q1 2018. 76 funds tracked by Wall St. Rank hold RCKT as of Q2 2018.

Highbridge Capital Management reported no remaining Rocket Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 250,000 Rocket Pharmaceuticals shares in Q2 2018, an estimated $4.69M.
Highbridge Capital Management first reported a position in Rocket Pharmaceuticals in Q3 2016 and held it in 3 quarters.
Highbridge Capital Management's Rocket Pharmaceuticals position peaked at $4.69M in Q1 2018.
76 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.